Personalized Medicine

Erscheinungsjahr 2016
ISBN: 978-0-12-804795-8
Verlag: ACADEMIC PR INC

Buch, Englisch, Band 102, 398 Seiten, Format (B × H): 155 mm x 231 mm, Gewicht: 794 g

Reihe: Advances in Protein Chemistry

The Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.

Zielgruppe

Researchers and specialists in protein structure and interactions, cancer biology, psychiatry and mass spectrometry.

Autoren/Hrsg.

Donev, Rossen

Weitere Mitwirkende

Donev, Rossen

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Naturwissenschaften Chemie Analytische Chemie Massenspektrometrie, Spektroskopie, Spektrochemie
• Naturwissenschaften Biowissenschaften Proteinforschung

Inhaltsverzeichnis

1. High-Performance Affinity Chromatography: Applications in Drug-Protein Binding Studies and Personalized Medicine Zhao Li, Sandya R. Beeram, Cong Bi, D. Suresh, Xiwei Zheng and David S. Hage 2. Role of Proteomics in the Development of Personalized Medicine Kewal K. Jain 3. Metabolomics and Personalised Medicine Nadia Koen, Ilse Du Preez and Du Toit Loots 4. Clinical Perspectives on Targeting Therapies for Personalised Medicine Donald R.J. Singer and Zoulikha M. Zaïr 5. Personalized Medicine in Respiratory Disease: Role of Proteomics Priyadharshini V.S. and Luis M. Teran 6. Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop Theodore Sakellaropoulos, Junguk Hur, Ioannis N. Melas, Ellen Y. Guo, Leonidas Alexopoulos, Mohammad Bohlooly and Jane P.F. Bai 7. Molecular Dynamics: New frontier in Personalized Medicine Sneha. P and George Priya Doss. C 8. Personalized Pharmacoperones for Lysosomal Storage Disorder - Approach for  Next Generation Treatment Syed Haneef SA and George Priya Doss C 9. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase domain: A Molecular Docking and Molecular Dynamics Approach D. Thirumal Kumar and George Priya Doss C 10. Role of von Willebrand Factor - A1 domain variants P1266L, H1268D, C1272R  and C1272F in VWD: a Molecular Modelling and Simulation Analysis Approach George Priya Doss. C and Shabana kouser Ali

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.